Drug prices: overcharging claims of ₹8,447 crore remain unpaid

1. At a Glance

• The National Pharmaceutical Pricing Authority (NPPA) has demanded ₹10,029.8 crore, including interest, from drug companies that sold medicines above notified prices. Only ₹1,582.4 crore has been recovered, so ₹8,447.4 crore (about 84%) is still outstanding as of 31 March 2026 [1].
• Overcharging means selling above the ceiling price or the allowed price increase. It violates the Drugs (Prices Control) Order (DPCO). High trade margins are a different issue and are not illegal in themselves [1].
• The issue matters because medicines make up a large share of what households spend on hospitalisation, according to the National Statistics Office's Household Social Consumption: Health survey, conducted in 2025 [1].
• It connects GS-II (Health, Governance and regulatory bodies) with GS-III (Inclusive growth and the pharma sector).

2. Why in the News

• 12 October 2026: The Centre told the Supreme Court it would cap trade margins at 30% for non-scheduled anti-cancer medicines [1][9].
• A Bench of Justices Vikram Nath and Sandeep Mehta asked why similar caps could not cover other medicines and medical products. It pointed to steep gaps between supply prices and the prices patients pay, and asked the government to work out broader price-regulation measures. The next hearing is on 27 October 2026 [1][9].
• October 2026: The NPPA finalised the 30% cap for 137 non-scheduled cancer drugs. The new prices take effect from 9 November 2026 [7].
• NPPA data show ₹8,447.4 crore in overcharging dues still unrecovered as of 31 March 2026 [1].

3. Background & Evolution

• 1979: NPPA records include overcharging cases going back to 1979, under earlier DPCOs [1].
• 1997: NPPA was set up as India's drug-price regulator [1].
• 2013-14: Pharma companies deposited ₹40.08 crore against demand notices covering about 90 cases [4].
• 2013 onwards: DPCO 2013 is in force. NPPA monitors prices of both scheduled and non-scheduled medicines under it [3].
• 2016: A one-time settlement was proposed to clear the overcharging backlog. NPPA's claims since 1997 then stood at about ₹4,953 crore, with ₹386.9 crore realised [6].
• February 2019: The first 30% trade-margin cap was applied to 42 non-scheduled anti-cancer drugs [12][13].
• 2022: NLEM 2022 (National List of Essential Medicines) was notified. It includes 63 anti-cancer drugs [10].
• 2025-26: A parliamentary standing committee reviewed NPPA. It found about ₹8,526 crore (85%) unrecovered, with about 70% under litigation, some cases pending for more than 20 years [2].
• October 2026: The second, larger trade-margin cap was finalised for 137 cancer drugs, under Supreme Court scrutiny [7][9].

4. Core Static Facts

Item	Fact
Regulator	NPPA, established 1997 [1]
Parent body	Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (standard reference, not retrieved this session)
Governing instrument	DPCO 2013 [1][3]
Parent Act	Section 3, Essential Commodities Act, 1955 (standard reference, not retrieved)
Scheduled drugs	Listed in Schedule-I of DPCO 2013 (taken from the NLEM). NPPA fixes ceiling prices for them [8]
Non-scheduled drugs	Prices are not capped, but NPPA monitors them [3]. They may raise MRP by up to 10% a year [7]
Legal basis for the 30% cap	Paragraph 19, DPCO 2013: price fixing in extraordinary circumstances and the public interest [7]
What the 30% cap means	30% of MRP excluding GST, which equals a 42.86% mark-up on the price to stockist/distributor [7]
Overcharging dues (31 March 2026)	Demanded ₹10,029.8 crore; realised ₹1,582.4 crore; outstanding ₹8,447.4 crore (about 84%) [1]
Estimated savings from the 2026 cap	About ₹2,500 crore a year [7]
Scheduled anti-cancer formulations	Ceiling prices fixed for 131. 111 were re-fixed under NLEM 2022, cutting prices by about 21% and saving ₹294.34 crore a year [8]

5. Multi-Dimensional Analysis

Economic

• Only about 16% of dues have been realised. This weakens deterrence, since firms gain from overcharging while the case is fought in court [1][2].
• The trade-margin cap goes after the gap between distributor and retail prices without fixing manufacturers' prices. It is expected to save about ₹2,500 crore a year [7].
• Industry reaction to the cap is mixed. Firms worry about distributor viability and how the cap will be complied with [11].

Social / Health equity

• Medicines take up a large share of hospitalisation spending, so overcharging adds directly to out-of-pocket expenditure (OOPE) [1].
• Cancer patients face long, costly treatment. The 2019 cap on 42 drugs reportedly cut MRPs of 526 brands by about 50% on average (per search summary; primary source not confirmed) [10].

Legal / Constitutional

• The Supreme Court's push links drug pricing to the right to health under Article 21 (standard reference) [9].
• About 70% of the outstanding dues are stuck in litigation, some for more than 20 years. Recovery depends on the courts [2].
• Paragraph 19 lets the government regulate non-scheduled drugs in an emergency or the public interest. It is the legal route for extending price control beyond the NLEM [7].

Governance / Administrative

• NPPA has limited monitoring capacity. Detection relies on market-based data and on state drug controllers (standard reference).
• The parliamentary committee review called for stronger recovery mechanisms [2][5].
• The proposed one-time settlement (2016) shows a trade-off between recovering money quickly and keeping penalties a credible deterrent [6].

Ethical

• Large gaps between supply price and retail price raise questions about profiteering on essential goods. They also show how little patients can bargain in a market where the doctor, not the patient, chooses the drug [1][9].

6. Recent Developments (last 12-18 months)

• February 2025: The government told the Lok Sabha that ceiling prices and retail prices had been fixed to keep cancer drugs affordable [10].
• 2025: NPPA re-fixed ceiling prices for scheduled anti-cancer formulations under NLEM 2022 (about 21% cut) [8].
• 2026: A parliamentary committee report found about 85% of overcharging dues unrecovered, about 70% of it in litigation [2].
• 31 March 2026: Outstanding dues stood at ₹8,447.4 crore [1].
• 8-12 October 2026: The Centre proposed the 30% cap and informed the Supreme Court. The Court asked why it could not be extended to other medicines [7][9][1].
• About 17 October 2026: The cap was finalised for 137 non-scheduled cancer drugs, effective 9 November 2026 [7].
• 27 October 2026: Next Supreme Court hearing [1].

7. Prelims Hooks

• NPPA was established in 1997 [1].
• Medicine pricing is governed by DPCO 2013 [1].
• Ceiling prices apply to drugs in Schedule-I of DPCO 2013 [8].
• NPPA monitors prices of both scheduled and non-scheduled medicines [3].
• The 2026 trade-margin cap is issued under Paragraph 19 of DPCO 2013 [7].
• The trade-margin cap is 30% of MRP excluding GST, equal to a 42.86% mark-up on the price to stockist [7].
• 137 non-scheduled anti-cancer drugs are covered by the 2026 cap, effective 9 November 2026 [7].
• The first trade-margin cap (2019) covered 42 anti-cancer drugs [12][13].
• NLEM 2022 includes 63 anti-cancer drugs [10].
• Non-scheduled drugs may raise MRP by up to 10% a year [7].
• Overcharging dues as of 31 March 2026: demanded ₹10,029.8 crore, realised ₹1,582.4 crore, outstanding ₹8,447.4 crore [1].
• NPPA records cover overcharging cases dating back to 1979 [1].
• The Supreme Court Bench is Justices Vikram Nath and Sandeep Mehta [1].

8. Why Overcharging Still Pays for Drug Companies

• The unpaid dues are growing faster than recovery
• In 2016, NPPA's claims stood at about ₹4,953 crore. Only ₹386.9 crore had been recovered, under 8% [6].
• By March 2026, claims had about doubled to ₹10,029.8 crore. Recovery had only reached about 16% [1].

• So each year, much more new overcharging is found than old money is collected.

• Going to court is cheaper than paying

• About 70% of the unpaid amount is under litigation (a dispute being fought in court). Some cases have been pending for more than 20 years [2].
• While the case goes on, the company keeps the extra money it took from patients and can use it in its business.

• The demand includes interest, but interest only arrives if the company loses and finally pays. For a firm, a 20-year delay is close to an interest-free loan.

• The penalty in the rules is rarely felt

• NPPA's orders say a firm that breaks a price cap must repay the extra amount with 15% interest, plus a penalty of up to 100% [15].

• With only about 16% recovered, that threat stays mostly on paper. The real risk a firm faces is a small fraction of the money it gains [1].

• A one-time settlement can teach firms to wait

• The 2016 proposal to settle old dues in one go [6] would bring in cash quickly.
• But if firms expect a discount later, the smart choice is to delay paying now. That makes the deterrence problem worse.

9. A Regulator Too Small to Catch Overcharging

• NPPA is short of staff
• 15 of NPPA's 48 sanctioned posts are vacant. Contract and outsourced staff fill the gap [2].

• Overcharging cases need careful price checks and long court work. A thin, temporary staff cannot handle a backlog going back to 1979 [1][2].

• NPPA sees only part of the market

• NPPA's price data cover only about 70% of the medicine market [2].

• Overcharging in the other 30% can go unnoticed, because NPPA catches overcharging mainly by comparing market prices.

• The public has little say in price fixing

• The parliamentary committee found that public participation in fixing prices is limited [2].
• Patients and doctors, who see the real prices at the counter, have few formal ways to report problems or shape decisions.

10. Where the Cancer Drug Margin Cap Can Leak

• The cap controls the margin, not the starting price
• Trade margin is the gap between the price the company charges the distributor and the MRP the patient pays.
• The 30% cap limits only that gap. If the company's own price to the stockist is high, the MRP stays high [7].

• Even under the cap, sellers can mark the price up by 42.86% over what they paid [7].

• Free-supply schemes can hide the real margin

• Drugs given through Patient Assistance Programmes (PAPs — company schemes that give free or cheaper doses to some patients) are left out of the calculation [7].

• Patient groups say leaving out PAP volumes makes margins look smaller than they really are, which reduces the MRP cuts [11].

• Companies work out their own new prices

• Advocates point out that companies were asked to calculate and report the revised MRPs themselves. The regulator did not set the cuts independently [11].

• When NPPA already struggles to collect dues, self-reporting gives firms room to bend the numbers.

• Hospitals may recover the loss elsewhere

• Margins on cancer drugs had been found to range from 170% to 700% at different outlets [7]. Many of those sales happen inside hospitals.
• Observers fear hospitals may raise admission or chemotherapy charges to make up for lost drug income [11]. The patient's total bill may not fall as much as the drug price does.

11. The Case Against Wider Caps — and How Far It Holds

• The strongest objection: one rule cannot fit every product
• Hospital chains argue that a single cap ignores real costs such as storage, handling and pharmacy services. They say this could hurt investment in capacity [11].
• Associations of small firms (MSMEs) warn that extending trade-margin caps to all non-scheduled drugs and devices could hit smaller companies hardest [11].

• This is partly right. On a cheap generic tablet, a margin of 30% may be too little to pay for distribution. Small chemists and small makers could leave the market.

• But the evidence for high-value drugs points the other way

• Margins of 170% to 700% on cancer drugs are far above any reasonable handling cost [7].
• The 2019 cap on 42 cancer drugs cut the MRP of 526 brands, in some cases by up to 90% [14].

• The industry body IPA (Indian Pharmaceutical Alliance) welcomed the 2026 cap, saying it still leaves enough margin for distributors [11]. Medical device makers have even asked for a uniform cap of their own [16].

• The honest answer: extend caps in steps, by price level

• The Supreme Court's question — why not other medicines? [9] — is strongest for high-priced drugs, where large margins add the most to a patient's bill.
• The government has considered this before: in 2022, reports said trade-margin rationalisation was being planned for drugs priced ₹100 and above [17].
• Low-priced generics can be kept outside the cap, or given a higher limit, to protect small players.

12. What Each Actor Should Do Next

• NPPA: set up a fast-track route for cases not yet in court
• The parliamentary standing committee recommended a fast-track dispute resolution mechanism for non-litigated cases [2].

• This stops the remaining 30% of dues from also ending up in 20-year court battles.

• NPPA: create a dedicated legal cell for old court cases

• The same committee asked for a legal cell inside NPPA to clear long-pending cases [2].

• With most dues stuck in court, recovery depends on winning cases, not on sending more notices.

• Department of Pharmaceuticals: write trade-margin rules permanently into DPCO 2013, with a deadline

• So far, trade-margin rationalisation has only been piloted, for some cancer drugs and COVID-19 devices. There is no timeline to make it a permanent part of DPCO 2013 [2].

• A one-off order under Paragraph 19 [7] can be challenged or left to lapse. A permanent framework gives firms and courts a clear, stable rule.

• NPPA: fill its vacancies and widen its data coverage

• Filling the 15 vacant posts and covering the 30% of the market it cannot see [2] would let NPPA catch overcharging earlier, before dues pile up.

• NPPA: calculate revised MRPs itself and count PAP supplies

• This answers the patient groups' main complaints about the 2026 cap [11], and makes the claimed ₹2,500 crore yearly saving [7] something that can be checked.

13. Anchors for Answers

• Data: ₹8,447.4 crore (about 84%) of ₹10,029.8 crore in overcharging demands unrecovered as of 31 March 2026 [1]; in 2016 only ₹386.9 crore of ₹4,953 crore had been realised [6]
• Data: Trade margins of 170%–700% found on non-scheduled cancer drugs [7]; 15 of 48 NPPA posts vacant, and price data cover only about 70% of the market [2]
• Report/Committee: Parliamentary Standing Committee on Chemicals and Fertilizers, review of NPPA (2026) — about 70% of dues in litigation; recommended a fast-track mechanism, a legal cell and a permanent trade-margin framework in DPCO [2]
• Law/Case: Paragraph 19, DPCO 2013 (price control in extraordinary circumstances) [7]; Supreme Court proceedings before Justices Vikram Nath and Sandeep Mehta on extending caps beyond cancer drugs [9]
• Comparison: 2019 trade-margin cap on 42 cancer drugs — MRP of 526 brands cut by up to 90% [14]; 2021 cap of 70% on price to distributor for five COVID-related medical devices, with 15% interest and up to 100% penalty for violators [15]
• Scheme: Pradhan Mantri Bhartiya Janaushadhi Pariyojana — cheap generic medicines, a route to affordability that does not depend on recovering dues from companies

14. Mains Relevance

• GS-II: Issues relating to development and management of the social sector and services relating to health; statutory, regulatory and quasi-judicial bodies.
• GS-III: Inclusive growth; effects of liberalisation on industry (the pharmaceutical sector).
• GS-IV: Corporate governance and ethics in business.
• Possible question stems: 1. More than four-fifths of overcharging dues demanded by the NPPA remain unrecovered. Examine the institutional and legal reasons, and suggest measures to strengthen enforcement of drug-price regulation. (250 words) 2. Trade-margin rationalisation is a more market-friendly tool than ceiling prices for making medicines affordable. Critically analyse in the context of anti-cancer drugs. (150 words) 3. Discuss the role of judicial intervention in making essential medicines affordable in India, with reference to Article 21. (150 words)

15. Related Topics to Study Next

• NLEM 2022: the source list for Schedule-I of DPCO and for ceiling prices.
• Essential Commodities Act, 1955: the parent Act for DPCO.
• Pradhan Mantri Bhartiya Janaushadhi Pariyojana: generic medicines as an alternative route to affordability.
• NSO health consumption survey / OOPE data: evidence on how much households spend on medicines.
• Ayushman Bharat PM-JAY: the financial-protection side of health care.
• Compulsory licensing and Section 3(d) of the Patents Act: how patents affect cancer drug prices.
• Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024: curbs on unethical pharma promotion.
• Department-related Parliamentary Standing Committees: how Parliament oversees regulators such as NPPA.

16. NCERT Concepts to Revise

• Price control (Economy): DPCO ceiling prices and the 30% trade-margin cap are government price control on medicines.
• Maximum Retail Price (Economy): Ceiling prices, the allowed 10% yearly MRP rise and the margin cap are all defined against MRP.
• Essential commodities (Economy): DPCO is issued under the Essential Commodities Act, which lets government cap prices of essential goods.
• Right to health (Polity): The Supreme Court's push for broader drug price regulation rests on health care being part of Article 21.
• Standing committee (Polity): A parliamentary standing committee reviewed NPPA and found about 85% of overcharging dues unrecovered.
• Distributor (Economy): The 30% cap targets the gap between the distributor's supply price and the retail price patients pay.

17. Common Errors / Trap Areas

• NPPA vs CDSCO: NPPA regulates prices. CDSCO, under the Health Ministry, regulates quality and approval of drugs.
• Ministry: NPPA falls under the Ministry of Chemicals & Fertilizers, not the Health Ministry.
• Ceiling price vs trade margin: ceiling prices apply to scheduled (NLEM) drugs. The 30% trade-margin cap applies to non-scheduled drugs [7][8].
• Overcharging vs high margin: overcharging is illegal under DPCO. A high trade margin is not illegal in itself [1].
• Years: NPPA was set up in 1997. Its case records go back to 1979. The current order is DPCO 2013. The first margin cap was in 2019, not 2026 [1][12].